MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · IEX Real-Time Price · USD
27.21
-0.68 (-2.44%)
At close:
May 31, 2023, 4:00 PM
27.07
-0.14 (-0.51%)
After-hours:
May 31, 2023, 7:39 PM EDT
Company Description
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies.
It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation.
The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
| Country | Switzerland |
| Founded | 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Dr. Jorge Santos da Silva |
Contact Details
Address:
Dorfstrasse 29 Zug, V8 6300 Switzerland | |
| Phone | 41 41 510 8022 |
| Website | moonlaketx.com |
Stock Details
| Ticker Symbol | MLTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001821586 |
| CUSIP Number | 61559X104 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jorge Santos da Silva | Co-Founder, Chief Executive Officer and Director |
| Dr. Kristian Reich | Co-Founder and Chief Scientific Officer |
| Matthias Bodenstedt | Chief Financial Officer |
| Oliver Daltrop | Chief Technical Officer |
| Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 19, 2023 | 8-K | Current Report |
| May 11, 2023 | 424B5 | Filing |
| May 11, 2023 | 10-Q | Quarterly Report |
| May 9, 2023 | EFFECT | Notice of Effectiveness |
| May 4, 2023 | EFFECT | Notice of Effectiveness |
| May 1, 2023 | S-3 | Registration statement under Securities Act of 1933 |
| May 1, 2023 | POS AM | Post-Effective amendments for registration statement |
| Apr 26, 2023 | ARS | Filing |
| Apr 26, 2023 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2023 | DEF 14A | Other definitive proxy statements |